Esperion Therapeutics Inc (ESPR)
1.97
-0.02
(-1.00%)
USD |
NASDAQ |
Apr 30, 16:00
1.99
+0.02
(+1.02%)
Pre-Market: 20:00
Esperion Therapeutics Cash from Operations (Quarterly): -37.06M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -37.06M |
| September 30, 2023 | -19.32M |
| June 30, 2023 | -24.75M |
| March 31, 2023 | -54.36M |
| December 31, 2022 | -42.47M |
| September 30, 2022 | -42.83M |
| June 30, 2022 | -50.53M |
| March 31, 2022 | -38.99M |
| December 31, 2021 | -57.71M |
| September 30, 2021 | -69.17M |
| June 30, 2021 | -47.87M |
| March 31, 2021 | -89.07M |
| December 31, 2020 | -68.55M |
| September 30, 2020 | -86.67M |
| June 30, 2020 | 139.39M |
| March 31, 2020 | -69.35M |
| December 31, 2019 | -49.99M |
| September 30, 2019 | -58.03M |
| June 30, 2019 | -54.01M |
| March 31, 2019 | 91.69M |
| December 31, 2018 | -28.69M |
| September 30, 2018 | -37.53M |
| June 30, 2018 | -39.20M |
| March 31, 2018 | -43.22M |
| Date | Value |
|---|---|
| December 31, 2017 | -34.87M |
| September 30, 2017 | -35.88M |
| June 30, 2017 | -26.23M |
| March 31, 2017 | -34.32M |
| December 31, 2016 | -16.32M |
| September 30, 2016 | -14.30M |
| June 30, 2016 | -7.307M |
| March 31, 2016 | -9.803M |
| December 31, 2015 | -8.449M |
| September 30, 2015 | -11.83M |
| June 30, 2015 | -8.614M |
| March 31, 2015 | -9.263M |
| December 31, 2014 | -8.208M |
| September 30, 2014 | -8.631M |
| June 30, 2014 | -6.078M |
| March 31, 2014 | -9.104M |
| December 31, 2013 | -7.531M |
| September 30, 2013 | -4.777M |
| June 30, 2013 | -3.179M |
| March 31, 2013 | -2.627M |
| December 31, 2012 | -2.369M |
| September 30, 2012 | -2.906M |
| June 30, 2012 | -2.847M |
| March 31, 2012 | -2.686M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-89.07M
Minimum
Mar 2021
139.39M
Maximum
Jun 2020
-43.23M
Average
-50.53M
Median
Jun 2022
Cash from Operations (Quarterly) Benchmarks
| United Therapeutics Corp | 150.70M |
| Dynavax Technologies Corp | 13.77M |
| Heron Therapeutics Inc | 2.455M |
| Aldeyra Therapeutics Inc | 0.5004M |
| Deciphera Pharmaceuticals Inc | -28.81M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 4.471M |
| Free Cash Flow | -135.49M |
| Free Cash Flow Per Share (Quarterly) | -0.3294 |
| Free Cash Flow to Equity (Quarterly) | -37.49M |
| Free Cash Flow Yield | -66.76% |